Skip to main content
Equibles
STOK logo

STOK · Stoke Therapeutics, Inc.

Track STOK — free

Use STOK with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about STOK

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$31.62 -0.97 (-2.98%) At close · Aug 28
Russell 2000 member Rebalance outlook locked
Market Cap
$2.06B
Shares
64.53M

Stoke Therapeutics, Inc. Earnings Call Transcripts

Quarterly earnings calls for Stoke Therapeutics, Inc. (STOK), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $2.90M −$26.11M '22 Q3 22-11-14 ▲47.9% $4.89M −$26.43M '24 Q3 24-11-05 ▲186% $13.82M −$23.48M '25 Q2 25-08-12 ▲117.2% $10.63M −$38.35M '25 Q3 25-11-04 ▼93.8% $1.40M −$57.93M '25 Q4 26-01-12 ▼96.1% $6.23M −$50.00M '26 Q1 26-05-07 LATEST ▼32.5% $9.32M −$61.62M '26 Q2 26-08-03
Conference
Investor event
2026-08-12
Stoke Therapeutics, Inc. (STOK) August 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q2
2026-08-03
Stoke Therapeutics, Inc. (STOK) Q2 2026 Earnings Call Transcript
Confident tone Phase III EMPER study progress and enrollment ADOA / STK-002 pipeline advancement SYNGAP1 and early-stage pipeline
Revenue
$9.32M
▼ 32.5% YoY
Diluted EPS
$-0.93
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Conference
Investor event
2026-06-08
Stoke Therapeutics, Inc. (STOK) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Conference
Investor event
2026-06-04
Stoke Therapeutics, Inc. (STOK) June 2026 Conference Transcript
No reported result — non-financial event
Audio Transcript Slides
Earnings call
FY26 · Q1
2026-05-07
Stoke Therapeutics, Inc. (STOK) Q1 2026 Earnings Call Transcript
Confident tone Four-year Phase 1/2 OLE data update Primary endpoint and label strategy Payer access and commercial readiness
Revenue
$6.23M
▼ 96.1% YoY
Diluted EPS
$-0.79
▼ 141.6% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q4
2026-01-12
Stoke Therapeutics, Inc. (STOK) Q4 2025 Earnings Call
Revenue
$1.40M*
▼ 93.8% YoY
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY25 · Q3
2025-11-04
Stoke Therapeutics, Inc. (STOK) Q3 2025 Earnings Call
Revenue
$10.63M
▲ 117.2% YoY
Diluted EPS
$-0.65
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Stoke Therapeutics, Inc. (STOK) Q2 2025 Earnings Call
Revenue
$13.82M
▲ 186% YoY
Diluted EPS
$-0.40
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q3
2024-11-05
Stoke Therapeutics, Inc. (STOK) Q3 2024 Earnings Call
Revenue
$4.89M
▲ 47.9% YoY
Diluted EPS
$-0.47
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q3
2022-11-14
Stoke Therapeutics, Inc. (STOK) Q3 2022 Earnings Call
Revenue
$2.90M
Diluted EPS
$-0.66
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–10 of 10 earnings calls
Key facts CIK 1623526 CUSIP 86150R107 13F (30d) 181 filings 176 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)